ClinicalTrials.gg
RecruitingNCT07599449RS-viro IRAUpdated Aug 3, 2026

Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France

An observational study in Respiratory Tract Infections (RTI), Influenza -Like Illness and Influenza, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-08-03.

Primary conditionInfluenza, HumanRegistry: Respiratory Tract InfectionsReclassifiedWhy we changed it
Registry
Respiratory Tract Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Influenza, Human
Why
  1. The study's listed conditions name Influenza, Human, a narrower term within Respiratory Tract Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Influenza, Human with a site in France — 11 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · France.

Planned enrollment
2nd of 24
25,000 · median 431
Started
2026
with 2 others
Observational
24 of 103
4 open now
Primary completion
2031-05
later than 11 of 11 live
Registered
101st of 103
by date
Lead sponsor
8 of 103
Institut National de la Santé Et de la Recherche Médicale, France

Among the 103 studies in Influenza, Human with a site in France, this one is the 2nd largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 101st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

11 of the 103 studies in Influenza, Human with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Influenza, Human with a site in France, or all of them as a file.
02

Study summary

Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.

03

Conditions studied

  • Respiratory Tract Infections (RTI)
  • Influenza -Like Illness
  • Influenza
  • COVID - 19
  • RSV Infections
  • Rhinovirus Infection
  • Metapneumovirus Infection
04

In context

Influenza, Human Reclassified

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

This study's planned enrollment of 25,000 is above the median of 403 across 335 observational studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.

Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients seen in GPs' consultation with an acute respiratory infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;
  • between week 40 (late September-early October) and week 15 (mid-April) of each year
  • have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms
  • have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation

Exclusion criteria

Exclusion Criteria:

  • a person who is subject to a court-ordered protective measure;
  • a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;
  • a person who is not in a condition to receive information or give consent.
06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Individuals with an ARI consulting a GP or a private pediatrician in mainland France

    Diagnostic Test: saliva sampling · Diagnostic Test: Nasopharyngeal swab

Interventions

  • Diagnostic testsaliva sampling

    Based on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Saliva collection: The physician oversees the collection during the visit using the provided kit (pipette, tube, etc.). Depending on constraints, the patient may perform the collection at home if agreed upon. If the patient is unable to self-collect (e.g., infants, facial paralysis), the physician collects the saliva directly from under the tongue using the pipette.

  • Diagnostic testNasopharyngeal swab

    Based on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Nasopharyngeal sampling: During the consultation, the physician performs a deep nasal swab using the provided kit (FFP2 mask, swab, transport tube, absorbent, SafetyBag, and pre-paid envelope for partner labs).

07

What researchers measure

Primary outcomes

  1. Proportion of acute respiratory infection (ARI) cases seen in private practice (general practice and pediatrics) that tested positive for influenza viruses (by type and subtype), SARS-CoV-2, RSV, rhinovirus, and metapneumovirus

    Time frame: Baseline

Secondary outcomes

  1. Weekly incidence rate of acute respiratory infections caused by influenza viruses and SARS-CoV-2 seen in general practice

    Time frame: Baseline

  2. Proportion of patients included vaccinated against influenza

    Time frame: Baseline

08

Study locations

1 of 1 sites recruiting
  • IPLESP - UMR S 1136, N° BC 2908, Faculté de médecine Sorbonne Université, site Saint Antoine, 27 rue Chaligny
    Paris, France
    Recruiting
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.

Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 60 months is above that.

Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 20, 2026
StartActual
May 14, 2026
Primary completionEst.
May 14, 2031
CompletionEst.
May 14, 2031
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07599449
Responsible party
Sponsor
First posted
May 20, 2026
Start date
May 14, 2026
Primary completion
May 14, 2031 (estimated)
Completion
May 14, 2031 (estimated)
Last update
Aug 3, 2026

Study contacts

Thierry BLANCHON, MD, PhD
Contact
thierry.blanchon@iplesp.upmc.fr
+33664846662
Olivier STEICHEN, MD, PhD
Contact
olivier.steichen@aphp.fr
Thierry BLANCHON, MD, PhD
principal investigator · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion